BIO-TECHNE Corp (NASDAQ:TECH)
| Market Cap | $11.42B+14.5% |
| Revenue (ttm) | $1.23B+0.9% |
| Net Income | $171.97M+120.5% |
| EPS | $1.10+124.5% |
| Shares Out | 157.09M |
| PE Ratio | 66.06 |
| Forward PE | 30.79 |
| Dividend | $0.40(0.55%) |
| Ex-Dividend Date | Nov 13, 2026 |
| Volume | 3,663,187 |
| Open | $72.75 |
| Previous Close | $72.70 |
| Day's Range | $72.66 - $72.77 |
| 52-Week Range | $43.20 - $72.88 |
| Beta | 1.27 |
| Analysts | Hold |
| Price Target | $71.67(-1.38%) |
| Earnings Date | Feb 3, 2027 |
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Next catalysts
- Feb 3, 2027Earnings report
$TECH stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of TECH by members of U.S. Congress
| Julie JohnsonHouse / D | Sale$1.00K – $15.00K | Apr 1, 2025 |
Recently reported changes in TECH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TECH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TECH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TECH Revenue by Segment or Geography
| Revenues, net | $299.71M | 33.88% |
| Product and Services | $285.22M | 32.24% |
| Consumables | $237.26M | 26.82% |
| Instruments | $25.50M | 2.88% |
| Services | $22.46M | 2.54% |
| Royalty revenues | $14.49M | 1.64% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TECH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TECH from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TECH
| VOOVanguard S&P 500 ETF | $302.46M |
| VTIVanguard Morningstar Total Stock Market ETF | $285.65M |
| VBVanguard Morningstar Small-Cap ETF | $255.45M |
| RSPInvesco S&P 500 Equal Weight ETF | $205.78M |
| SEQSequoia ETF | $164.32M |
| IVViShares Core S&P 500 ETF | $153.11M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from TECH’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q1 earnings beat and advancement of Merck KGaA merger deal provide concrete positive catalysts.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| AINT | FINQ DOLLAR NEUTRAL U.S. Large Cap AI-Managed Equity ETF | 52.20% |
| GNOM | Global X - Genomics & Biotechnology ETF | 3.66% |
| MNA | NYLI Merger Arbitrage ETF | 3.46% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 3.28% |
| ARB | AltShares Merger Arbitrage ETF | 2.49% |
| MRGR | ProShares - Merger ETF | 2.34% |
| GNMX | Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | 2.29% |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 1.47% |
| RYH | Invesco S&P 500 Equal Weight Health Care ETF | 1.47% |
| AEMC | Harbor AlphaEdge Mid Cap Core ETF | 1.39% |
| AEMV | Harbor AlphaEdge Mid Cap Value ETF | 1.15% |
| BBH | VanEck Biotech ETF | 1.11% |
Weight is the stock’s share of each fund’s holdings.
